ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0790

Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study

Omar Alsaed, Masautso Chaponda, Eman Satti, Hadil Ashour, Muna Almaslamani and Samar Al emadi, Hamad Medical Corporation, Doha, Qatar

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, COVID-19, Disease-Modifying Antirheumatic Drugs (Dmards)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The sustainability of the immunogenicity of BNT162b2 anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune rheumatic diseases (ARDs) receiving immunomodulators is uncertain. The Objective of this study is to evaluate whether the durability of the humoral immune response to BNT162b2 vaccine differs between patients without and with ARDs receiving immunomodulators.

Methods: We retrospectively reviewed the electronic medical records of patients with ARDs and control patients without ARDs. Patients who were SARS-CoV-2 infection-naïve, had completed COVID19 vaccination using, had been serologically tested for anti-SARS-CoV-2 S immunoassays using Elecsys® at least 6 months post second dose of the vaccine and had not received the third booster dose were included in the analysis. The overall mean of anti-SARS-CoV-2 S protein titer and at two cut offs; < 250 and < 132 binding antibody unit/mL (BAU/mL) were compared between the two groups using unpaired t-test and Chi-square test. Binary logistic regression analysis was performed to identify which immunomodulators associated with a significant drop in the antibody level.

Results: Mean (SD) ages of 48 patients with ARDs and 103 controls were 44.8 (11.9) vs. 38.6 (7.9) years. Women predominated in both groups (60% vs. 59%, P = 0.889). The most frequently prescribed disease modifying anti-rheumatic drug (DMARDs) was TNF-i in 24 (50%) followed by methotrexate in 22 (45.8%), hydroxychloroquine in 10 (20.8%), lL6-i in 4 (8.3%), and rituximab in 3 (6.3%) patients. Six months post vaccination, the overall mean (SD) anti-SARS-CoV-2 S antibody titer in the case group was significantly lower than the controls; 162 (94) vs. 241 (28), OR (95%CI) 0.980(0.972- 0.988). At both cut offs (< 250 and < 132 BAU/mL), the number of cases whose antibody dropped below the cut offs was significantly lower in ARDs group compared to controls; 27 (56.3%) vs. 16 (15.5%), P < 0.001 and 19 (39.6%) vs. 2 (1.9%), P < 0.001, respectively. Nevertheless, neither conventional synthetic-DMARDs nor biological-DMARDs (without rituximab) was associated with a significant drop in antibody titer at the two cut offs (Table 1).

Conclusion: Immunogenicity induced by BNT162b2 vaccine in patients with ARDs receiving immunomodulators fades faster than in patients without ARDs. Cs-DMARDs and biological-DMARDs (without rituximab) may not play a role in decreasing the durability of immunogenicity, however a study with larger sample size is needed to confirm this.

Supporting image 1

Table 1: demographic characteristics and anti-SARS-CoV_2 S protein titer 6 months post vaccination in both case and control groups with corresponding OR (95%CI).


Disclosures: O. Alsaed, None; M. Chaponda, None; E. Satti, None; H. Ashour, None; M. Almaslamani, None; S. Al emadi, None.

To cite this abstract in AMA style:

Alsaed O, Chaponda M, Satti E, Ashour H, Almaslamani M, Al emadi S. Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/sustainability-of-immunogenicity-of-bnt162b2-vaccine-in-patients-with-autoimmune-rheumatic-disease-a-retrospective-comparative-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustainability-of-immunogenicity-of-bnt162b2-vaccine-in-patients-with-autoimmune-rheumatic-disease-a-retrospective-comparative-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology